/Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE
NEWS
Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE
PRNewswire
2026/02/09Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE News provided by DJS Law Group LLP Feb 09, 2026, 03:30 ET Share this article Share to X Share this article Share to X LOS ANGELES , Feb. 9, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of RARE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: August 3, 2023 to December 26, 2025 DEADLINE: April 6, 2026 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Ultragenyx gave created falsely optimistic beliefs for its investors regarding the performance of its drug candidate in its Phase III trial. The Company failed to achieve statistically significant endpoints despite its optimistic communications. Based on these facts, Ultragenyx's public statements were false and materially misleading throughout the class period. If you are a shareholder who suffered a loss, contact us to participate . WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. Join the case to recover your losses. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: David J. Schwartz DJS Law Group 274 White Plains Road, Suite 1 Eastchester, NY 10709 Phone: 914-206-9742 Email: [email protected] SOURCE DJS Law Group LLP 21 % more press release views with Request a Demo × Modal title
Summary
LOS ANGELES, Feb. 9, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...